Technetium Tc99m Sestamibi

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Myocardial Infarction

Conditions

Myocardial Infarction

Trial Timeline

Jan 1, 2005 → Jul 1, 2007

NCT ID

NCT00162331

About Technetium Tc99m Sestamibi

Technetium Tc99m Sestamibi is a approved stage product being developed by Lantheus Holdings for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT00162331. Target conditions include Myocardial Infarction.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00162045	Phase 1/2	Completed	Jan 1, 2005	Jun 1, 2007	Kawasaki Disease
NCT00162331	Approved	Completed	Jan 1, 2005	Jul 1, 2007	Myocardial Infarction
NCT00162357	Approved	Completed	Apr 1, 2004	Dec 1, 2005	Diabetes Mellitus, Type 2
NCT00162344	Approved	Completed	Dec 1, 2003	Dec 1, 2005	Diabetes

Competing Products

20 competing products in Myocardial Infarction

See all competitors

Product	Company	Stage	Hype Score
Butylphthalide + Butylphthalide placebo	CSPC Pharmaceutical Group Limited	Phase 3	76
Abciximab	Eli Lilly	Approved	85
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 3	77
Regadenoson + gadofoveset trisodium	Astellas Pharma	Phase 2	52
Half-dose of the Tc99-m sestamibi (Cardiolite)	Astellas Pharma	Pre-clinical	23
No intervention	Astellas Pharma	Pre-clinical	23
Empagliflozin + Placebo	Eli Lilly	Phase 3	77
Abciximab + Abciximab placebo	Eli Lilly	Phase 3	77
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serum	Eli Lilly	Phase 3	77
Abciximab	Eli Lilly	Approved	85
abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximab	Eli Lilly	Phase 3	77
fibrinolytic therapy or combination reduced fibrinolytic therapy	Eli Lilly	Phase 3	77
abciximab	Eli Lilly	Approved	85
tenecteplase + enoxaparin + clopidogrel	Eli Lilly	Phase 2/3	65
Thrombolytic therapy	Eli Lilly	Pre-clinical	23
Ticagrelor	AstraZeneca	Pre-clinical	23
Ticagrelor	AstraZeneca	Phase 2	52
Dual-antiplatelet therapy + Dual-antiplatelet therapy	AstraZeneca	Pre-clinical	23
Metoprolol- Toprol XL + Metoprolol- Lopressor	AstraZeneca	Phase 1	33
Ticagrelor orodispersible tablets + Ticagrelor standard tablets	AstraZeneca	Phase 3	77

Other Products from Lantheus Holdings

Piflufolastat F 18 Intravenous Solution [PYLARIFY]Approved

3D HI and SHI of UCAApproved

Definity® Vial for (Perflutren Lipid Microsphere) Injectable SuspensionApproved

DefinityApproved

Technetium Tc99m SestamibiApproved